Pharmacodynamic Genes do not Influence Risk of Neutropenia in Cancer Patients Treated with Moderately High-Dose Irinotecan | Zendy

Janelle M. Hoskins | Zendy; Gary L. Rosner | Zendy; Mark J. Ratain | Zendy; Howard L. McLeod | Zendy; Federico Innocenti | Zendy

Open Access

Pharmacodynamic Genes do not Influence Risk of Neutropenia in Cancer Patients Treated with Moderately High-Dose Irinotecan

Author(s) -

Janelle M. Hoskins,

Gary L. Rosner,

Mark J. Ratain,

Howard L. McLeod,

Federico Innocenti

Publication year - 2009

Publication title -

pharmacogenomics

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.541

H-Index - 91

eISSN - 1744-8042

pISSN - 1462-2416

DOI - 10.2217/pgs.09.35

Subject(s) - irinotecan , pharmacodynamics , medicine , neutropenia , pharmacology , oncology , cancer , pharmacokinetics , chemotherapy , colorectal cancer

A recent study found that variation in camptothecin pharmacodynamic genes (TOP1, PARP1, TDP1 and XRCC1) correlated with efficacy and risk of neutropenia in irinotecan-treated cancer patients (median dose: 180 mg/m2), which suggests that these genes might predict outcomes to irinotecan-based therapies. The present study was conducted to evaluate previous gene associations using an independent sample of patients receiving irinotecan.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research